Ixabepilone
Chemotherapeutic Drug
Cramer's Mad Money - Agnico Eagle's Golden Disappointment (11/2/09)...patent in 2012. Currently Bristol Myers has a Phase III drug for metastic melanoma, Erbitux for colorectal, head and neck cancer, Sprycel for Leukemia, Ixempra for breast cancer and Taxol for breast, lung and ovarian cancer. Sprycel is the... In this article: Jim Cramer, Pfizer, Bristol Myers, Jarden, Stanley Works, Black & Decker, BHP, 3M, Cancer, and Agnico Eagle Mines |
-
The Seattle Times | December 12, 2008
Bristol-Myers, biotech Exelixis team up on cancer
...drug Erbitux through a partnership with ImClone Systems Inc. The company also makes leukemia treatment Sprycel, breast cancer drug Ixempra and the chemotherapy agent Taxol. Bristol-Myers has three other cancer drugs in late-stage...
In this article: Bristol-Myers, Cancer, Revenue, ImClone Systems Inc., Ixempra, Sprycel, Leukemia, Erbitux, and Breast cancer
-
Reuters | April 06, 2009
Bristol wins Abilify extension, sees profit boost
...in Bristol-Myers' oncology business, with an option to co-market its Sprycel leukemia drug and to help further develop Bristol's Ixempra breast cancer medicine. Sprycel, introduced in 2006, has annual sales of about $300 million and...
In this article: Bristol-Myers, Abilify, Plavix, Ixempra, United States, Revenue, Sprycel, and Bristol
-
Bristol-Myers, Japanese drugmaker expand deal
...two types of leukemia and is in final-stage testing for prostate cancer. Ixempra, launched at the end of 2007, had about $100 million in sales last year. It is approved for treating advanced breast cancer after patients have failed on...
In this article: Bristol-Myers Squibb, Revenue, Abilify, Cancer, Sprycel, Plavix, Balance sheet, Ixempra, and Bristol
-
clinicaltrials.gov
Ixabepilone in Treating Patients With Relapsed or Refractory ...
Leukemia. Lymphoma. Drug: ixabepilone. Phase II. Study Type: Interventional. Study Design: ... topics: Cancer Leukemia, Adult Acute Leukemia, Adult Chronic ...
-
www.clinicaltrials.gov
Ixabepilone in Treating Young Patients With Solid Tumors or ...
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That ... and tolerability of ixabepilone at the solid tumor MTD (expanded leukemia cohort) ...
-
bethesdatrials.cancer.gov
CCR Clinical Trials at NIH: Clinical Research: Clinical ...
Phase II Trial of LMB-2, Fludarabine, and Cyclophosphamide for Adult T-Cell Leukemia ... of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric ...
-
med.stanford.edu
Clinical Trials Directory - Stanford Medicine
Leukemia ... Acute Lymphoblastic Leukemia That Has Relapsed ... Leukemia. Ixabepilone in Treating Young Patients With Refractory Solid Tumors. Dr. Neyssa Marina ...
-
www.curetoday.com
CureToday.com: Winter 2007 Article - "Breast Cancer, Liver ...
Breast Cancer, Liver Cancer & Leukemia. Breast Cancer & Liver Cancer ... Drug Administration approved Ixempra (ixabepilone) in combination with Xeloda ...
-
www.cancernetwork.com
Encouraging Results With Ixabepilone in Metastatic Breast Ca ...
Ixabepilone (aza-epothilone B) is a semisynthetic analog of ... Obesity hinders treatment in pediatric leukemia. Oncology NEWS International, October 29, 2009 ...
Trends
Loading...
More on Ixabepilone
Description from Wikipedia:
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug.
On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra.
, ixabepilone is not yet available in the European Union.
Explore everything named Ixabepilone...
